Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split SBRT and nab-Paclitaxel plus Gemcitabine in BRPC and LAPC
NCT04289792Phase 2Unknown
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Fujian Medical University Union Hospital. Status: unknown.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04289792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04289792.